Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.65 USD | +6.40% | +11.33% | +28.15% |
Financials (USD)
Sales 2024 * | 43.32M | Sales 2025 * | 19.08M | Capitalization | 538M |
---|---|---|---|---|---|
Net income 2024 * | -78M | Net income 2025 * | -108M | EV / Sales 2024 * | 6.63 x |
Net cash position 2024 * | 250M | Net cash position 2025 * | 72.65M | EV / Sales 2025 * | 24.4 x |
P/E ratio 2024 * |
-6.62
x | P/E ratio 2025 * |
-5.35
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.61% |
Latest transcript on Fulcrum Therapeutics, Inc.
1 day | +6.40% | ||
1 week | +11.33% | ||
Current month | +10.19% | ||
1 month | +11.61% | ||
3 months | -21.08% | ||
6 months | +74.75% | ||
Current year | +28.15% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Sapir
CEO | Chief Executive Officer | 57 | 23-06-30 |
Alan Musso
DFI | Director of Finance/CFO | 62 | 23-08-06 |
Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Geraghty
BRD | Director/Board Member | 69 | 16-07-18 |
Director/Board Member | 70 | 16-11-30 | |
James Collins
BRD | Director/Board Member | 58 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.00% | 9 M€ | +10.33% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 8.65 | +6.27% | 311,769 |
24-06-04 | 8.14 | -0.49% | 498,903 |
24-06-03 | 8.18 | +4.20% | 928,002 |
24-05-31 | 7.85 | +2.61% | 365,770 |
24-05-30 | 7.65 | -1.54% | 340,468 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.15% | 538M | |
+55.70% | 59.34B | |
+43.17% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- FULC Stock